DOCSLIB.ORG

Laboratory Licensure As of July 2003

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Laboratory Licensure As of July 2003 Drug Identification Scope of Testing Effective June 4, 2021 6aR,9R)-delta-10-THC 3,4-Methylenedioxy U-47700 (6aR,9S)-delta-10-THC 3,4-Methylenedioxy-a-Pyrrolidinohexanophenone (MDPHP)^ 1 cP-LSD ^ 3,4-Methylenedioxy-N,N-diethylcathinone^ 1-(3-Chloro-4-fluorophenyl)piperazine^ 3,4-Methylenedioxy-N-benzylcathinone^ 1-(4-Bromophenyl)piperazine^ 3,4-Methylenedioxy-N-tert-butylcathinone^ 1,4-Butanediol 3,4-tetramethylene-alpha-Pyrrolidinovalerophenone^ 1,4-Dibenzylpiperazine 3-Aminopyridine 11-Ketotestosterone 3-Bromomethcathinone^ 17-Alpha-Estradiol 3-Chloroethcathinone^ 17-Alpha-Methyltestosterone 3-Chloromethcathinone^ 17-Beta-Estradiol 3-chloro-N,N-dimethylcathinone^ 17-beta-Hydroxyandrosta-4,6-dien-3-one (6- 3-ethoxy-4-methoxy N,N-Diethylpentedrone^ Dehydrotestosterone) 3-Ethylmethcathinone^ 19-Nor-4-androstene-3,17-dione 3-Fluoroamphetamine^ 1-Methyl-4-benzylpiperazine (MBZP)^ 3-Fluoroethamphetamine^ 1-Naphthylamine 3-Fluoromethamphetamine^ 1P-LSD 3-Fluorophenmetrazine^ 2,3-Dichlorophenylpiperazine^ 3-FMC (3-Fluoromethcathinone)^ 2,3-difluoro U-47700 3-hydroxy PCE^ 2,3-Methylenedioxymethcathinone^ 3-hydroxy PCP^ 2,5-dimethoxy Fentanyl 3-hydroxy Phenazepam/Cinazepam 25B-NBOH^ 3-MEC (3-Methylethcathinone)^ 25B-NBOMe^ 3-MeO-PCE (3-Methoxyeticyclidine)^ 25C-NBOH^ 3-MeO-PCP^ 25C-NBOMe^ 3-methoxy-4-ethoxy N,N-Diethylpentedrone^ 25D-NBOMe^ 3-Methoxymethamphetamine^ 25E-NBOH^ 4-acetoxy DMT^ 25H-NBOMe^ 4-acetoxy MALT^ 25H-NBOMe imine analog^ 4-acetoxy MET^ 25I-NBOMe^ 4-acetoxy MPT^ 25I-NBOMe imine analog^ 4-Aminopyridine 25N-NBOMe^ 4-Anilinopiperidine 2-bromo-4,5-Dimethoxyphenethylamine^ 4-ANPP 2C-B (2,5-Dimethoxy-4-bromophenethylamine)^ 4-APB* 2C-B-FLY (8-Bromo-2,3,6,7-benzo-dihydro-difur-ethylamine)^ 4-Bromoamphetamine^ 2C-C (2,5-Dimethoxy-4-chlorophenethylamine)^ 4-Bromomethcathinone^ 2C-D (2,5-Dimethoxy-4-methylphenethylamine)^ 4-chloro-alpha-pyrrolidinopropiophenone^ 2C-E (2,5-Dimethoxy-4-ethylphenethylamine)^ 4-Chloro-alpha-pyrrolidinovalerophenone (4Cl-PVP)^ 2C-H (2,5-Dimethoxyphenethylamine)^ 4-Chlorodiazepam 2-Chloroethcathinone^ 4-Chloroethcathinone^ 2-Chloromethcathinone^ 4-Chloromethcathinone^ 2-chloro-N,N-dimethylcathinone^ 4-chloro-N,N-dimethylcathinone^ 2C-I (2,5-Dimethoxy-4-iodophenethylamine)^ 4-Chloropentedrone^ 2C-N (2,5-Dimethoxy-4-nitrophenethylamine)^ 4-CIC^ 2C-P (2,5-Dimethoxy-4-propylphenethylamine)^ 4-cyano CUMYL-BUTINACA* 2C-T-2 (2,5-Dimethoxy-4-ethylthiophenethylamine)^ 4-cyano MDMB-BUTINACA* 2C-T-4 (2,5-Dimethoxy-4-isopropylthiophenethylamine)^ 4-Dimethylaminoantipyrine 2C-T-7 (2,5-Dimethoxy-4-n-propylthiophenethylamine)^ 4-EAPB 4-(2-Ethylaminopropyl)Benzofuran^ 2-Ethylmethcathinone^ 4-ethyl-a-Pyrrolidinopentiophenone^ 2-fluoro Deschloroketamine^ 4-Ethylethcathinone^ 2-Fluoroamphetamine^ 4-Ethylmethcathinone^ 2-Fluoroethamphetamine^ 4-Ethyl-N,N-dimethylcathinone^ 2-Fluoromethamphetamine^ 4-fluoro ABUTINACA* 2-MEC (2-Methylethcathinone)^ 4-fluoro MDMB-BUTICA* 2-Methoxymethamphetamine^ 4-fluoro MDMB-BUTINACA* 2-methyl AP-237 4-fluoro Pentedrone^ 2-Methyl-4-(methylthio)-2-morpholinopropiophenone^ 4-fluoro-3-methyl-a-PVP^ 3,4-(Methylenedioxy)propiophenone^ 4-Fluoroamphetamine^ 3,4-Dichloromethylphenidate^ 4-fluoro-a-Pyrrolidinopentiophenone^ 3,4-DMMC (3,4-Dimethylmethcathinone)^ 4-Fluoroethamphetamine^ 3,4-Ethylenedioxy U-47700 4-Fluoromethamphetamine^ 3,4-Ethylenedioxy U-51754 4-Fluoromethylphenidate^ 3,4-Methylenedioxy PV8^ 4-fluoro-Pyrrolidinohexanophenone^ Note: Compounds indicated noted with an ^ (designer stimulants/hallucinogens) or an* (synthetic cannabinoids) may not be included in the routine scope of analysis. Please contact Client Services at 844-276-1182 Page 1 of 8 for further information. This listing is subject to change without notice Crim_Scope_ver2021_06.04.2021.1 Drug Identification Scope of Testing Effective June 4, 2021 4-Fluorotropacocaine AB-001* 4-Fluorotropacocaine AB-005* 4-HO-MET (4-hydroxy-N-methyl-N-ethyl tryptamine)^ AB-CHMINACA* 4-hydroxy DET^ AB-FUBINACA* 4-hydroxy MiPT^ AB-PINACA* 4-hydroxy Nitazene Acepromazine 4-MEC (4-Methylethcathinone)^ Acetaminophen 4-MeO-MiPT (4-methoxy-N-methyl-N-isopropyltryptamine)^ Acetildenafil 4-methoxy-Butyryl fentanyl Acetyl norfentanyl 4-methyl Acetyl fentanyl Acetylcodeine 4-methyl Fentanyl Acetylfentanyl 4-methyl Hexedrone^ Acetylsalicylic acid 4-Methyl-alpha-ethylaminopentiophenone^ ACHMINACA* 4-methyl-alpha-Pyrrolidinohexanophenone^ Acrylfentanyl 4-Methylaminorex ADB-4en-PINACA* 4-Methylpentedrone^ ADB-BUTINACA* 4-OH-DiPT (4-Hydroxy-Diisopropyltryptamine)^ ADB-FUBINACA* 4-Phenyl U-51754 ADB-HEXINACA* 5-(2-Aminopropyl)indole (5-IT)^ ADBICA* 5-Aminoisotonitazene ADB-PINACA* 5-APB (5-(2-Aminopropyl)benzofuran)^ Adinazolam 5-APDB^ Adrenosterone (Androst-4-ene-3,11,17-trione) 5-chloro AB-PINACA* a-ethyl 2C-D^ 5-chloro AKB48* AH 7921 5-EAPB 5-(2-Ethylaminopropyl)Benzofuran^ AKB48 (APINACA)* 5F-APINACA (5F-AKB48)* Alfentanil 5-Fluoro 7-APAICA* AL-LAD (N-Allylnorlysergic N,N-diethylamide)^ 5-Fluoro ADB* alpha-methyl Acetyl fentanyl 5-Fluoro AEB* alpha-methyl Thiofentanyl 5-Fluoro AMB* alpha-methyl-3,4-Methylenedioxyphenylpropionamide^ 5-fluoro CUMYL-P7AICA* alpha-Methylfentanyl 5-fluoro CUMYL-PeGACLONE* alpha-PCYP (a-Pyrrolidinocyclohexanophenone)^ 5-fluoro CUMYL-PINACA* Alphaprodine 5-fluoro EDMB-PICA* alpha-Pyrrolidinohexanophenone (a-PHP)^ 5-fluoro EDMB-PINACA* alpha-Pyrrolidinoisohexanophenone (a-PiHP)^ 5-fluoro EMB-PICA* Alprazolam 5-Fluoro MDMB-PICA* AM-1220* 5-fluoro MPP-PICA* AM-1241* 5-Fluoro NPB-22* AM-1248* 5-Fluoro SDB-005* AM-2201* 5-fluoro-3,5-AB-PFUPPYCA* AM-2201 8-quinolinyl carboxamide* 5-Fluoro-ABICA* AM2201 Benzimidazole* 5-Fluoro-AB-PINACA* AM-2233* 5-Fluoro-ADBICA* AM-679* 5-Fluoro-ADB-PINACA* AM-694* 5-Fluoro-NNEI* Amantadine 5-Fluoro-PB-22* a-methyl Butyryl fentanyl 5-IAI (5-Iodo-2-aminoindan)^ a-methyl Butyryl fentanyl 5-MAPB (1-(benzofuran-5-yl)-N-methylpropan-2-amine)^ Aminorex 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine)^ Amitriptyline 5-MeO-DALT (N,N-Diallyl-5-methoxytryptamine)^ Amlodipine 5-MeO-DiPT (5-Methoxy-N,N-diisopropyltryptamine)^ Amobarbital 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine)^ Amoxapine 5-MeO-MiPT (5-methoxy-N-methyl-N-isopropanyltryptamine)^ Amphetamine 5-methoxy DBT^ AMT (Alpha-methyltryptamine)^ 6-APB (6-(2-aminopropyl)benzofuran)^ Anastrozole 6-APDB^ Androst-5-en-3-ol-7,17-dione acetate 6-EAPB 6-(2-Ethylaminopropyl)Benzofuran^ Androstenedione 6-MAM (6-Monoacetylmorphine) Anileridine 7-keto Dehydroepiandrosterone Aniracetam 8-Aminoclonazolam AP-237 9(R)-delta-6a,10a-THC AP-238 A-796,260* a-PBP (Alpha-pyrrolidinobutiophenone)^ A-834735* APP-BUTINACA* Note: Compounds indicated noted with an ^ (designer stimulants/hallucinogens) or an* (synthetic cannabinoids) may not be included in the routine scope of analysis. Please contact Client Services at 844-276-1182 Page 2 of 8 for further information. This listing is subject to change without notice Crim_Scope_ver2021_06.04.2021.1 Drug Identification Scope of Testing Effective June 4, 2021 APP-CHMINACA (PX 3)* Carbaryl a-PPP (Alpha-pyrrolidinopropiophenone)^ Carbinoxamine a-PVP (Alpha-pyrrolidinopentiophenone)^ Carbofuran a-PVT (Alpha-pyrrolidinopentiothiophenone)^ Carbophenothion Aripiprazole Carfentanil Atenolol Carisoprodol Atomoxetine Cathine (Norpseudoephedrine) Atropine Cathinone Azelastine Caulophylline (N-Methylcytisine) Azinphos-methyl CB-13* Baclofen CB-25* Barbital CB-52* BB-22* CBC BDB (Benzodioxolylbutanamine)^ CBCV Bendiocarb CBD Bentazepam CBDV Benzocaine CBG Benzodioxole fentanyl CBL Benzphetamine CBN Benztropine CBT Benzyl carfentanil Celecoxib Benzyl fentanyl Chlorcyclizine beta-Hydroxyfentanyl Chlordiazepoxide Beta-hydroxythiofentanyl Chlorophacinone Betamethasone Chloroquine beta-Methylfentanyl Chlorpheniramine Bisacodyl Chlorpromazine bk-2C-B^ Chlorpyrifos bk-IVP^ Chlorzoxazone bk-MDDMA^ cis-3-methyl Butyryl fentanyl Boldenone cis-3-methyl Fentanyl Boldenone acetate cis-3-methyl Thiofentanyl Boldenone cypionate cis-ent-Tadalafil Boldenone undecylenate cis-Flupentixol Boldione Citalopram/Escitalopram Brivaracetam Cl2201* Brodifacoum Clenbuterol Bromadiolone Clobazam Bromadol Clobenzorex Bromantane Clomiphene Bromantane Clomipramine Bromazepam Clonazepam Bromazolam Clonazolam Bromo-dragonfly^ Clonidine Brompheniramine Clonitazene Brorphine Clopidogrel Brucine Clostebol BTCP (Benocyclidine)^ Clozapine Bufotenine Cocaine Buphedrone^ Codeine Bupivacaine Colchicine Buprenorphine Coniine Bupropion Coumaphos Buspirone CP 47,497 (C7)* Butabarbital CP 47,497 (C8)* Butalbital CP 55,940* Butorphanol Crotonyl fentanyl Butylone (bk-MBDB)^ CUMYL-CBMICA* Butyrylfentanyl CUMYL-PeGACLONE* BZP (N-Benzylpiperazine)^ Cyclizine Cabergoline Cyclobenzaprine Caffeine Cyclobutyl fentanyl Canthardine Cyclohexyl fentanyl Carbamazepine Cyclopentyl fentanyl Note: Compounds indicated noted with an ^ (designer stimulants/hallucinogens) or an* (synthetic cannabinoids) may not be included in the routine scope of analysis. Please contact Client Services at 844-276-1182 Page 3 of 8 for further information. This listing is subject to change without notice Crim_Scope_ver2021_06.04.2021.1 Drug Identification Scope of Testing Effective June 4, 2021 Cyclopropyl fentanyl DOI (2,5-Dimethoxy-4-iodoamphetamine)^ Cyproheptadine DOM (2,5-Dimethoxy-4-methylamphetamine)^ D2PM (Diphenylprolinol)^ Doxepin Dapoxetine Doxylamine d-Bicuculline DPT (N,N-Dipropyltryptamine)^ DEET (Diethyltoluamide) Droperidol Delorazepam Drostanolone Enanthate Delta-8-THC Drostanolone Propionate Delta-9-THC Duloxetine Deoxy Modafinil EAM-2201* Desalkylflurazepam EMB-FUBINACA* Deschloroetizolam EPN Deschloroketamine^
Load more

Recommended publications
  • Analysis of Benzylpiperazine-Like Compounds Hiroyuki Inoue 1
    鑑識科学，9(2)，165―184(2004) 165 ―Technical Note― Analysis of Benzylpiperazine-like Compounds Hiroyuki Inoue1,YukoT.Iwata1, Tatsuyuki Kanamori1, Hajime Miyaguchi1, Kenji Tsujikawa1, Kenji Kuwayama1, Hiroe Tsutsumi2, Munehiro Katagi2, Hitoshi Tsuchihashi2 and Tohru Kishi1 National Research Institute of Police Science 631, Kashiwanoha, Kashiwa, Chiba 2770882, Japan1 Forensic Science Laboratory, Osaka Prefectural Police H. Q. 1318, Hommachi, Chuo-ku, Osaka, Osaka 5410053, Japan2 (Received 6 January 2004; accepted 6 March 2004) 1-Benzylpiperazine (BZP) and 1-(3-tri‰uoromethylphenyl)piperazine, newly controlled as narcotics in Japan on 2003, and their analogues were analyzed. The analytical data with color test, thin layer chromatography (TLC), infrared spectroscopy (IR), gas chromatography/mass spectrometry (GC/MS) and liquid chromatography/mass spectrometry (LC/MS) are presented. The BZP-like compounds were less sensitive to Simon's reagent than amphetamine type stimulants on spot plates. Using on-site screening kit based on Simon's test (X-Checker), BZP indicated almost the same result as methamphetamine. For TLC, the solvent system, methanol －25 aqueous ammonia (100 : 1.5), was the best among the systems examined. Iodoplatinate reagent was the most sensitive one to detect BZP. The IR spectra showed su‹cient diŠerences to make identiˆcation. Trimethylsilylation was the most appropriate choice for the GC/MS analysis of BZP-like compounds in terms of the peak shapes, separation and stability (using a J&W DB-5MS column). In LC/MS analysis, the gradient elution (10 mM formic acid and acetonitrile) using a Waters Symmetry Shield C18 column achieved discrimination of isomers except for 1-(2-‰uorophenyl) piperazine and 1-(4-‰uorophenyl)piperazine.
    [Show full text]
  • Amnestic Concentrations of Sevoflurane Inhibit Synaptic
    Anesthesiology 2008; 108:447–56 Copyright © 2008, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Amnestic Concentrations of Sevoflurane Inhibit Synaptic Plasticity of Hippocampal CA1 Neurons through ␥-Aminobutyric Acid–mediated Mechanisms Junko Ishizeki, M.D.,* Koichi Nishikawa, M.D., Ph.D.,† Kazuhiro Kubo, M.D.,‡ Shigeru Saito, M.D., Ph.D.,§ Fumio Goto, M.D., Ph.D.࿣ Background: The cellular mechanisms of anesthetic-induced for surgical procedures do not have recollection of ac- amnesia are still poorly understood. The current study exam- tually being awake despite being awake and cooperative ined sevoflurane at various concentrations in the CA1 region of during the procedure.1 Galinkin et al.2 compared sub- rat hippocampal slices for effects on excitatory synaptic trans- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/108/3/447/366512/0000542-200803000-00017.pdf by guest on 29 September 2021 mission and on long-term potentiation (LTP), as a possible jective, psychomotor, cognitive, and analgesic effects of mechanism contributing to anesthetic-induced loss of recall. sevoflurane (0.3% and 0.6%) with those of nitrous oxide Methods: Population spikes and field excitatory postsynaptic at equal minimum alveolar concentrations (MACs) in potentials were recorded using extracellular electrodes after healthy volunteers. They found that sevoflurane pro- electrical stimulation of Schaffer-collateral-commissural fiber inputs. Paired pulse facilitation was used as a measure of pre- duced a greater degree of amnesia and psychomotor synaptic effects of the anesthetic. LTP was induced using tetanic impairment than did an equal MAC of nitrous oxide but stimulation (100 Hz, 1 s). Sevoflurane at concentrations from had no analgesic actions.
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Development and Validation of a UHPLC-UV Method for The
    Development and validation of a UHPLC-UV method for the detection and quantification of erectile dysfunction drugs and some of their analogues found in counterfeit medicines. Pierre-Yves Sacré a,b, Eric Deconinck a, Patrice Chiap c, Jacques Crommen b, François Mansion b, Eric Rozet d, Patricia Courselle a, Jacques O. De Beer a,* a Laboratory of Drug Analysis, Scientific Institute of Public Health, Brussels, Belgium b Department of Analytical Pharmaceutical Chemistry, Institute of Pharmacy, University of Liège, Liège, Belgium. c Advanced Technology Corporation (A.T.C.), University Hospital of Liège, Liège, Belgium d Department of Analytical Chemistry, Institute of Pharmacy, University of Liège, Liège, Belgium. Abstract Pharmaceutical counterfeiting is a permanently growing problem. Control laboratories are constantly analysing counterfeit medicines. In industrialised countries, one of the main counterfeited class of medicines are erectile dysfunction drugs. This paper describes the development and validation of a fast method to detect and quantify the three authorised phosphodiesterase type 5 inhibitors and five analogues. The method is based on the use of a sub-2 microns polar-embedded column with a gradient using acetonitrile as organic modifier and 10 mM ammonium formate buffer (pH 3.5) as aqueous component of the mobile phase. The separation was achieved in less than 4.5 min. The method has also been compared to the registered HPLC method for the assay of Viagra ® which was considered as the reference method. The method is also compatible with on-line coupling mass spectrometry and will significantly reduce analysis times and solvent consumption. Keywords: Phosphodiesterase type 5 inhibitors; UHPLC; method validation, analogues, counterfeit drugs, accuracy profiles.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • Picrotoxin-Like Channel Blockers of GABAA Receptors
    COMMENTARY Picrotoxin-like channel blockers of GABAA receptors Richard W. Olsen* Department of Molecular and Medical Pharmacology, Geffen School of Medicine, University of California, Los Angeles, CA 90095-1735 icrotoxin (PTX) is the prototypic vous system. Instead of an acetylcholine antagonist of GABAA receptors (ACh) target, the cage convulsants are (GABARs), the primary media- noncompetitive GABAR antagonists act- tors of inhibitory neurotransmis- ing at the PTX site: they inhibit GABAR Psion (rapid and tonic) in the nervous currents and synapses in mammalian neu- system. Picrotoxinin (Fig. 1A), the active rons and inhibit [3H]dihydropicrotoxinin ingredient in this plant convulsant, struc- binding to GABAR sites in brain mem- turally does not resemble GABA, a sim- branes (7, 9). A potent example, t-butyl ple, small amino acid, but it is a polycylic bicyclophosphorothionate, is a major re- compound with no nitrogen atom. The search tool used to assay GABARs by compound somehow prevents ion flow radio-ligand binding (10). through the chloride channel activated by This drug target appears to be the site GABA in the GABAR, a member of the of action of the experimental convulsant cys-loop, ligand-gated ion channel super- pentylenetetrazol (1, 4) and numerous family. Unlike the competitive GABAR polychlorinated hydrocarbon insecticides, antagonist bicuculline, PTX is clearly a including dieldrin, lindane, and fipronil, noncompetitive antagonist (NCA), acting compounds that have been applied in not at the GABA recognition site but per- huge amounts to the environment with haps within the ion channel. Thus PTX major agricultural economic impact (2). ͞ appears to be an excellent example of al- Some of the other potent toxicants insec- losteric modulation, which is extremely ticides were also radiolabeled and used to important in protein function in general characterize receptor action, allowing and especially for GABAR (1).
    [Show full text]
  • House Bill No. 1176
    FIRST REGULAR SESSION HOUSE BILL NO. 1176 101ST GENERAL ASSEMBLY INTRODUCED BY REPRESENTATIVE DAVIS. 2248H.01I DANA RADEMAN MILLER, Chief Clerk AN ACT To repeal sections 191.480 and 579.015, RSMo, and to enact in lieu thereof two new sections relating to investigational drugs. Be it enacted by the General Assembly of the state of Missouri, as follows: Section A. Sections 191.480 and 579.015, RSMo, are repealed and two new sections 2 enacted in lieu thereof, to be known as sections 191.480 and 579.015, to read as follows: 191.480. 1. For purposes of this section, the following terms shall mean: 2 (1) "Eligible patient", a person who meets all of the following: 3 (a) Has a debilitating, life-threatening, or terminal illness; 4 (b) Has considered all other treatment options currently approved by the United States 5 Food and Drug Administration and all relevant clinical trials conducted in this state; 6 (c) Has received a prescription or recommendation from the person's physician for an 7 investigational drug, biological product, or device; 8 (d) Has given written informed consent which shall be at least as comprehensive as the 9 consent used in clinical trials for the use of the investigational drug, biological product, or device 10 or, if the patient is a minor or lacks the mental capacity to provide informed consent, a parent or 11 legal guardian has given written informed consent on the patient's behalf; and 12 (e) Has documentation from the person's physician that the person has met the 13 requirements of this subdivision; 14 (2) "Investigational drug, biological product, or device", a drug, biological product, or 15 device, any of which are used to treat the patient's debilitating, life-threatening, or terminal 16 illness, that has successfully completed phase one of a clinical trial but has not been approved EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law.
    [Show full text]
  • DEPARTMENT of JUSTICE Drug Enforcement
    This document is scheduled to be published in the Federal Register on 08/03/2021 and available online at DEPARTMENT OF JUSTICEfederalregister.gov/d/2021-16499, and on govinfo.gov Drug Enforcement Administration Bulk Manufacturer of Controlled Substances Application: Cerilliant Corporation [Docket No. DEA-873] AGENCY: Drug Enforcement Administration, Justice. ACTION: Notice of application. SUMMARY: Cerilliant Corporation has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before [INSERT DATE 60 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. Such persons may also file a written request for a hearing on the application on or before [INSERT DATE 60 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. ADDRESS: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on June, 24, 2021, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): Controlled Substance Drug Code Schedule 3-Fluoro-N-methylcathinone
    [Show full text]
  • ED Analogues Analysis
    UPLC-MS/MS for the Screening, Confirmation and Quantification of 32 Drugs illegally added to Herbal/Dietary Supplements for the Enhancement of Male Sexual Performance 1Salman Azimi*, 2Nayan Mistry and 2Michelle Wood 1Drug Quality Control Laboratory, Pharmacy & Drug Control Dept., Supreme Council of Health, PO Box 1919, Doha - Qatar. 2 Figure-5: Photographs of six positive samples. Forty-three suspected Waters Corporation, Atlas Park, Wythenshawe, Manchester, M22 5PP, UK. samples were analyzed in this study; 18 were found to be adulterated with ED drugs. ABSTRACT RESULTS & DISCUSSION The adulteration of herbal/dietary supplements with erectile dysfunction (ED) drugs and their analogues is reported For the purpose of screening , a spectral library for known ED drugs and analogues was prepared. Owing to recent reports Table 2: List of 32 compounds with retention times, and optimised MRM transitions parameters. Table-3: Summary of results for eight adulterated herbal/dietary samples. The screening results, including spectral match worldwide and is an increasing problem[1]. The sale of so-called 100%, ‘all-natural’ products has become a highly of increased availability of ‘all-in-one’/ ‘combination’ herbal products[2], we also added the naturally-occurring substances factors, RT data and final screening status ( = positive or - = negative) are presented, in addition to the quantitative data Retention Precursor Cone Quantifier Qualifier %CV (n=4) from the subsequent confirmatory analysis. profitable business for online pharmacies, however these products can pose a serious threat to consumers owing to the Icariin and yohimbine, the synthetic, dapoxetine (used for premature ejaculation) and testosterone. The library was CE CE Dwell LOQ undisclosed presence of approved/prescription drugs or the unknown safety and toxicity profile of unapproved ED drugs.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020
    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
    [Show full text]
  • WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 33/16 (2006.01) A61K 31/7048 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, A61K 33/14 (2006.01) A61K 31/70 (2006.01) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, A61K 33/18 (2006.01) A61K 31/4196 (2006.01) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (21) International Application Number: RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, PCT/US20 13/030788 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (22) International Filing Date: ZM, ZW. 13 March 2013 (13.03.2013) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 61/612,689 19 March 2012 (19.03.2012) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: YALE UNIVERSITY [US/US]; Two Whitney TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Avenue, New Haven, CT 065 10 (US).
    [Show full text]